Close Menu

SISCAPA Assay Technologies

Enthusiasm for dried blood spot samples is building among clinical proteomic researchers and companies, but recent work suggests technical hurdles remain.

Waters has obtained a non-exclusive license to the technology, which allows researchers to create internal standard calibration curves for their assays.

A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.

The company plans to launch the 12-protein panel as a CLIA test for longitudinal monitoring of cardiovascular disease, kidney disease, and diabetes.

While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.

The company plans to offer the immuno-MRM assays as kits covering sample prep and protein digestion as well as immuno-enrichment of specific peptides.

Having gained traction for its technology in the RUO and LDT spaces, the company is now looking to develop its reagents for use in regulatory-cleared IVDs.

NEW YORK (GenomeWeb) – Precision Antibody in partnership with SISCAPA Assay Technologies has completed a Phase I SBIR contract from the National Cancer Institute to develop antibodies for mass spec-based protein biomarker assays.

NEW YORK (GenomeWeb) – New England Peptide and SISCAPA Assay Technologies are collaborating to manufacture and sell stable isotope standard peptides for use in SISCAPA's protein quantification assays.

NEW YORK (GenomeWeb) – Agilent Technologies and SISCAPA Assay Technologies said today that they have signed a non-exclusive agreement to provide complete workflows for targeted protein quantitation.

Pages

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.